Biotechnology News and Research

RSS

PDL BioPharma signs revenue interest assignment agreement with ARIAD Pharmaceuticals

PDL BioPharma, Inc. today announced that it has entered into a revenue interest assignment agreement (the "Agreement") in which it has agreed to provide ARIAD Pharmaceuticals, Inc. with up to $200 million in revenue interest financing in exchange for royalties on the net revenues of Iclusig (ponatinib).

29 Jul 2015

New polymer gel could help create swallowable devices for ultra-long drug delivery

Medical devices designed to reside in the stomach have a variety of applications, including prolonged drug delivery, electronic monitoring, and weight-loss intervention. However, these devices, often created with nondegradable elastic polymers, bear an inherent risk of intestinal obstruction as a result of accidental fracture or migration. As such, they are usually designed to remain in the stomach for a limited time.

29 Jul 2015

United Therapeutics’ revenues increase by $24.4 million in second quarter 2015

United Therapeutics Corporation today announced its financial results for the second quarter ended June 30, 2015. "Orenitram sales grew nearly 300% as compared to the second quarter of 2014 when the product was first launched," said Roger Jeffs, Ph.D., United Therapeutics' President and Co-Chief Executive Officer.

28 Jul 2015

German life sciences entrepreneurs granted option to develop Aeterna Zentaris’ oral allogenic tumor vaccine technology

Aeterna Zentaris Inc. today announced that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and commercialization of biotechnology, an option to license the Company's live recombinant oral allogenic tumor vaccine technology, including AEZS-120, the most advanced product candidate for prostate cancer which is ready to enter a Phase 1 clinical trial.

28 Jul 2015

Champions Oncology's revenue increases 32% to $3.2 million in fourth quarter 2015

Champions Oncology, Inc., engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the year ended April 30, 2015.

28 Jul 2015

Innovative approach to treating AAT deficiency

Researchers have demonstrated the feasibility of delivering an RNA that encodes for the protein alpha-1-antitrypsin (AAT)--which is missing or nonfunctional in the genetic disorder AAT deficiency--into cells in the laboratory, enabling the cells to produce highly functional AAT.

28 Jul 2015

FDA grants Fast Track Designation to TxCell’s Ovasave for treatment of Crohn’s disease

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has granted Fast Track Designation to TxCell’s lead product Ovasave for the treatment of moderate to severe Crohn’s disease.

28 Jul 2015

Study reveals impact of patient navigator program on no-show rates for cervical cancer screening

Researchers at Harvard Medical School and Brigham and Women's Hospital reported a 20% decline in the rate of missed appointments for cervical cancer evaluation following a Pap smear when a patient navigator program was initiated at the referral center.

25 Jul 2015

Wayne State's faculty selected for Aspen Health Innovators Fellowship

The Washington, D.C.-based educational and policy studies organization The Aspen Institute has selected Wayne State University School of Medicine's Patrick Hines, M.D., Ph.D., associate professor of Physiology and an assistant professor of Pediatric Critical Care Medicine, one of only 20 health care leaders in the country for the inaugural class of its Health Innovators Fellowship.

25 Jul 2015

Trends, R&D progress, and predicted revenues in RNAi therapies

When will RNAi therapies reach the market? Visiongain's brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.

25 Jul 2015

Lupin signs strategic asset purchase agreement with Temmler

Pharma Major Lupin Limited today announced that it has entered into a strategic asset purchase agreement with TEMMLER PHARMA GMBH & CO. KG, a part of the Aenova Group, one of the world's largest pharmaceutical contract manufacturers, to acquire Temmler's specialty product portfolio subject to certain closing conditions.

25 Jul 2015

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the entire equity interest in Zhejiang Wansheng Pharmaceutical Co., Ltd a limited liability company incorporated in the PRC for an aggregate consideration of RMB 528 million.

24 Jul 2015

Two UM researchers receive $500,000 to improve treatment for mild traumatic brain injury

Two University of Montana researchers were among six final winners nationally to receive $500,000 from the Head Health Challenge I, an up-to-$10 million program sponsored by General Electric Co. and the National Football League.

24 Jul 2015

Gladstone Institutes announces new business endeavor with Evotec and Dolby Family Ventures

The Gladstone Institutes announces the creation of Cure Network Ventures Inc. and Cure Network Dolby Acceleration Partners, LLC, a business endeavor with Dolby Family Ventures and Evotec AG, which will focus on Alzheimer's disease. Working through Cure Network Ventures, Inc., the new company will help expedite the translation of relevant scientific discoveries from the Gladstone Institute of Neurological Disease into the development of potential therapies.

24 Jul 2015

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy.

23 Jul 2015

Lupin enters into definitive agreement to acquire GAVIS

Pharma Major Lupin Limited has entered into a definitive agreement to acquire privately held GAVIS Pharmaceuticals LLC and Novel Laboratories Inc., subject to certain closing conditions, in a transaction valued at USD 880 million, cash free and debt free.

23 Jul 2015

Zinc coating of galvanized steel pipes can be long-term source of lead in water

When unsafe levels of lead are found in drinking water, the culprit has typically been lead pipes or lead-containing brass and bronze fittings, but in a new study researchers clearly show that lead present in the zinc coating of galvanized steel pipes can be a very significant long-term source of lead in water.

23 Jul 2015

Study shows regions of genome underlying IBD consistent around the world

The first genetic study of inflammatory bowel disease (IBD) to include individuals from diverse populations has shown that the regions of the genome underlying the disease are consistent around the world. This study, conducted under the auspices of the International IBD Genetics Consortium, included nearly 10,000 DNA samples from people of East Asian, Indian or Iranian descent and an existing set of 86,640 samples drawn from across Europe, North America and Oceania.

22 Jul 2015

KalVista raises $33 million in Series B financing to support development of plasma kallikrein inhibitors

KalVista Pharmaceuticals, a research-led pharmaceutical company, today announced it has raised $33 million in a Series B financing to support its research and clinical development programs. KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE).

22 Jul 2015

New TripAdvisor-style website launched to help researchers choose better tools for biomedical research

An international panel of leading scientists is launching a new TripAdvisor-style website aimed at helping researchers choose better-quality research tools - and avoiding potentially serious errors in biomedical research.

22 Jul 2015

Biotechnology News and Research

PDL BioPharma signs revenue interest assignment agreement with ARIAD Pharmaceuticals

New polymer gel could help create swallowable devices for ultra-long drug delivery

United Therapeutics’ revenues increase by $24.4 million in second quarter 2015

German life sciences entrepreneurs granted option to develop Aeterna Zentaris’ oral allogenic tumor vaccine technology

Champions Oncology's revenue increases 32% to $3.2 million in fourth quarter 2015

Innovative approach to treating AAT deficiency

FDA grants Fast Track Designation to TxCell’s Ovasave for treatment of Crohn’s disease

Study reveals impact of patient navigator program on no-show rates for cervical cancer screening

Wayne State's faculty selected for Aspen Health Innovators Fellowship

Trends, R&D progress, and predicted revenues in RNAi therapies

Lupin signs strategic asset purchase agreement with Temmler

3SBio purchases entire equity interest in Zhejiang Wansheng

Two UM researchers receive $500,000 to improve treatment for mild traumatic brain injury

Gladstone Institutes announces new business endeavor with Evotec and Dolby Family Ventures

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Lupin enters into definitive agreement to acquire GAVIS

Zinc coating of galvanized steel pipes can be long-term source of lead in water

Study shows regions of genome underlying IBD consistent around the world

KalVista raises $33 million in Series B financing to support development of plasma kallikrein inhibitors

New TripAdvisor-style website launched to help researchers choose better tools for biomedical research

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News